Sugi Predict

Sugi Predict / Compounds / SCHEMBL2340132

SCHEMBL2340132

SCHEMBL2340132

O=[N+]([O-])c1ncc(Cl)cc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ CTDSP1 Q9GZU7 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ GRIN2D O15399 1/20 0.36
▸ GRIN3B O60391 1/20 0.36
▸ GRIN1 Q05586 1/20 0.36
▸ GRIN2A Q12879 1/20 0.36
▸ GRIN2B Q13224 1/20 0.36
▸ GRIN2C Q14957 1/20 0.36
▸ GRIN3A Q8TCU5 1/20 0.36
▸ TSHR P16473 2/20 0.36
▸ GPR35 Q9HC97 2/20 0.36
▸ GALR3 O60755 1/20 0.36
▸ TTR P02766 1/20 0.36
▸ S100A9 P06702 1/20 0.36
▸ MAPT P10636 3/20 0.34
▸ S1PR4 O95977 1/20 0.34
▸ AHR P35869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3545535 0.80 TSHR (0.48) KDM4EL3MBTL1CTDSP1ALDH1A1TSHR
SCHEMBL9622184 0.80 MAPT (0.36) KDM4EL3MBTL1ALDH1A1TSHRGPR35
SCHEMBL8566803 0.78 ALOX15 (0.44) KDM4EL3MBTL1ALDH1A1CYP3A4TSHR
SCHEMBL2586421 0.77 MAPT (0.41) KDM4ECTDSP1ALDH1A1TSHRGPR35
SCHEMBL31289923 0.77 MAPT (0.45) KDM4EL3MBTL1CTDSP1ALDH1A1TSHR
SCHEMBL3668043 0.77 S1PR4 (0.43) KDM4EL3MBTL1CTDSP1ALDH1A1TSHR
SCHEMBL7494690 0.77 SMN1; SMN2 (0.42) KDM4EALDH1A1CYP3A4TSHRGPR35
SCHEMBL5582938 0.77 MAPK1 (0.36) KDM4EL3MBTL1ALDH1A1TSHRGPR35
SCHEMBL12179353 0.77 MAPT (0.34) KDM4EL3MBTL1ALDH1A1TSHRGPR35
SCHEMBL2448243 0.77 KDM4E (0.42) KDM4EL3MBTL1CTDSP1ALDH1A1GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125359-A1 HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS FUJIAN HAIXI PHARMACEUTICALS CO LTD (CN) 2026-05-07 — — US disclosed
CN-114901280-B MrgprX2 antagonists and uses thereof 德米拉公司 2025-05-27 — — CN disclosed
US-20230027929-A1 MrgprX2 Antagonists and Uses Thereof DERMIRA, INC. 2023-01-26 — — US disclosed
EP-4054570-A1 MRGPRX2 ANTAGONISTS AND USES THEREOF Dermira, Inc (US) 2022-09-14 — — EP disclosed
CN-114901280-A MrgprX2 antagonists and uses thereof 德米拉公司 2022-08-12 — — CN disclosed
US-10662185-B2 Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-26 — — US disclosed
US-10662185-B2 Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-26 — — US disclosed
US-20190248783-A9 AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-08-15 — — US disclosed
US-20190248783-A9 AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-08-15 — — US disclosed
EP-3227287-B1 HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE Bayer Pharma AG (DE) 2019-08-07 — — EP disclosed
US-8420642-B2 Pyridine derivatives useful as glucokinase activators MERCK PATENT GMBH (DE) 2013-04-16 — — US disclosed
EP-2195312-B1 PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS MERCK PATENT GMBH (DE) 2012-11-21 — — EP disclosed
EP-1948652-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2011-08-24 — — EP disclosed
CN-101821264-A Pyridine derivatives useful as glucokinase activators MERCK PATENT GMBH 2010-09-01 — — CN disclosed
US-20100216794-A1 PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-08-26 — — US disclosed
EP-2195312-A1 PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS Merck Patent GmbH (DE) 2010-06-16 — — EP disclosed
US-20100056530-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2010-03-04 — — US disclosed
WO-2009046784-A1 PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS MERCK PATENT GMBH (DE) 2009-04-16 — — WO disclosed
EP-1948652-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-07-30 — — EP disclosed
WO-2007053345-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248783-A9 AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE AADAC, TNNI3, PAICS KDM4E 1651/4885L3MBTL1 3816/4885CTDSP1 2759/4885
US-10662185-B2 Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use AADAC, TNNI3, TNNT2 KDM4E 2228/4885L3MBTL1 4388/4885CTDSP1 2734/4885
US-20260125359-A1 HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS ERBB2, ERBB3, ARRB1 KDM4E 3910/4885L3MBTL1 1648/4885CTDSP1 1610/4885
US-20100056530-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 KDM4E 2723/4885L3MBTL1 556/4885CTDSP1 4072/4885
US-20230027929-A1 MrgprX2 Antagonists and Uses Thereof MRGPRX2, MRGPRX1, MRGPRX4 KDM4E 3632/4885L3MBTL1 4533/4885CTDSP1 4621/4885
US-20100216794-A1 PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS HK1, GCKR, GCK KDM4E 2494/4885L3MBTL1 2853/4885CTDSP1 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.